Up 427% this year, why today is a big day for Mesoblast shares
It’s another big day for Mesoblast Ltd (ASX: MSB) shares. Here’s why the ASX biotech stock is making news on Friday.
News Medical33m
Phase 3 study finds inebilizumab effective for immunoglobulin G4–related disease
An international, phase 3 clinical trial led by investigators at Mass General Brigham could improve the treatment of a rare disease that can cause debilitating symptoms.